Montelukast Pharmathen

Montelukast, the active ingredient in Montelukast Pharmathen, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is indicated for the management of asthma, allergic rhinitis and exercise‑induced bronchoconstriction in both adult and pediatric patients through daily therapy and provides symptom control.

GNH USA supplies Montelukast Pharmathen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance. The product meets EU market standards for safety and efficacy.

Montelukast acts on the leukotriene pathway to reduce airway inflammation and bronchoconstriction.

Asthma: improves control of persistent asthma and reduces exacerbations. Allergic rhinitis: alleviates nasal congestion, sneezing and itchy eyes associated with seasonal allergies. Exercise‑induced bronchoconstriction: prevents narrowing of airways triggered by physical activity.

Montelukast may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate head discomfort. - Abdominal pain: transient stomach discomfort. - Cough: occasional dry cough. - Dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects: - Neuropsychiatric events: agitation, depression, suicidal thoughts. - Allergic reactions: rash, angioedema, anaphylaxis.

When prescribing Montelukast, consider the following precautions.

Assess asthma control before initiating therapy: ensure patient is on appropriate inhaled controller. Monitor for neuropsychiatric symptoms: report mood changes or suicidal ideation. Use caution in patients with hepatic impairment: adjust if necessary. Avoid use in patients with known hypersensitivity to montelukast or excipients. Pregnancy and lactation: discuss risk‑benefit with healthcare provider. Store at ambient temperature below 25°C: keep in original container, protect from moisture and light.

Montelukast may interact with other medicines; review the following.

Major Interactions (Avoid): - Phenobarbital: may reduce plasma concentrations of montelukast. - Rifampin: induces metabolism, decreasing efficacy. - Strong CYP3A4 inhibitors: may increase exposure, raising risk of side effects.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of anticoagulant effect, monitor INR. - Theophylline: additive bronchodilator effect, monitor for tachycardia. - Beta‑agonists: no direct interaction but combined therapy may enhance bronchodilation.